As We See It

Microcyn Technology in the Treatment of Acne

By Jim Schutz, Oculus COO

During our quarterly earnings calls, we enjoy taking a few extra minutes to describe a patient story or two. We’re often advised by Wall Street experts that big pharma companies use their earnings calls just to highlight their financials—and, because we all follow big pharma, we should as well.

We respectfully disagree. We look forward to hearing from our patients and as Hoji constantly reminds us, companies like Apple are dominant in multiple markets because of their zealous commitment to listening to their customers. So bear with me as I describe an interesting new patient story. This one is from Mexico and describes terrific results using our new acne medication, GramaDerm. Read More »

Posted in Dermatology, Microcyn Technology, New Microcyn Products, Oculus Future, Patient Success Stories by Jim Schutz on March 1st, 2011
No Comments »

Oculus’ Strategic Shift

By Jim Schutz, COO

In late 2008, as the economy was faltering and cash at Oculus was running thin, our CEO, Hoji Alimi, CFO Bob Miller and I locked ourselves into a window-less office at our headquarters in Northern California, turned off our phones, closed our laptops and stood before a white board to chart our course. Our stock price was at an all-time low, our access to cash to fund operations was non-existent (across all industries as you may recall) and we had to right the ship. Read More »

Posted in Oculus Future by Jim Schutz on December 1st, 2010
1 Comment »

Upcoming Catalysts

By Jim Schutz
Oculus COO

Last week, we released our earnings for the quarter ending June 30, 2010 and have received lots of feedback from our shareholders and analysts. Several highlights:

We hit our numbers for the 6th quarter in a row on both revenue and operating expenses,
Our cash position is healthy, and
We’ve converted from a one compound company into a commercial stage enterprise with more than 20 products in the market, just in the US.

Posted in Oculus Future by Jim Schutz on August 17th, 2010
No Comments »

A Tale of Two Cities

By Dan McFadden
Oculus Director of Investor Relations

As director of investor and public relations at Oculus, I have one of the best jobs in the company. Since I joined the Oculus team in January 2004, I’ve had the pleasure of meeting with hundreds of doctors/patients from around the globe (in my efforts to document through video, photos and written chronicle, their experiences) that have been successfully treated with the Microcyn Technology. It’s truly an uplifting experience when you can see the real-world impact of saving patient lives.

Posted in Patient Success Stories by Dan McFadden on July 1st, 2010
No Comments »

Success Stories from the Field

By Jim Schutz
Oculus COO

I hope this message finds you all well.

All is well at Oculus after a solid Q4 earnings call in early June. In anticipation of our earnings calls, we typically prepare several days in advance to ensure our message is clear and concise. Our message on this call was clear-cut: Revenue was up in the United States, Mexico, China, India and the Middle East with 65%+ growth and expenses were flat across the board.

Posted in Patient Success Stories by Jim Schutz on June 28th, 2010
No Comments »

What a Difference a Year Makes!

As part of my responsibilities as the CEO of Oculus, I attend various financial conferences where we present the Oculus story to investment funds or institutions. Just this week, we attended an annual growth stock conference in Southern California. We presented to a room full of investors (you can view/hear the presentation by visiting http://www.wsw.com/webcast/roth23/ocls/ ) and then followed with a series of one-on-one meetings for 30-minutes or so with individual fund managers.

Posted in Oculus Future by Hoji Alimi on March 25th, 2010
No Comments »

One Patient’s Experience: The Genesis Behind The New Microcyn HydroGel for Dermatology

Jim Schutz
Oculus Chief Operating Officer

As you may have recently read, we received a clearance from the FDA for our new Microcyn Dermatology HydroGel product, our first dermatology product and a terrific new opportunity for the team at Oculus.

We’ve been quizzed repeatedly the last several days for the “story” behind the new product and our push into dermatology. Bear with me for a peek behind the scenes.

Posted in Dermatology by Jim Schutz on March 10th, 2010
No Comments »

Keeping it in Perspective

By Hoji Alimi, Oculus Founder and CEO

I just returned from three days in San Francisco where I presented at one of the largest investor healthcare conferences of the year. The economic sentiment this year, versus last, was upbeat and optimistic. As CEO of Oculus, I was elated to share with the investment community that Oculus has reached an inflection point in our growth, with seven new FDA clearances and product introductions targeted for the United States in 2010. The investors we met with this week along with the general market response has been favorable to our news.

Posted in Global Outreach by Hoji Alimi on January 15th, 2010
1 Comment »

Microcyn® Technology vs. Antibiotics: A comparative view of Microcyn Technology products, liquids and gels, containing HOCl and topical and systemic products containing antibiotics.

Claims for the Microcyn® Technology platform are not approved for Microcyn® products in the U.S.

Dr. Eileen Thatcher
Professor Emeritus
Sonoma State University

The antimicrobial agent in Microcyn Technology is hypochlorous acid (HOCl), is found naturally produced in animals and humans for protection against infectious agents, including bacteria, viruses, yeasts and some fungi. This small molecule is nontoxic to host cells at the concentrations used in Microcyn Technology and does not cause the development of allergic reactions with repeated use.

Posted in Antibiotics by Eileen Thatcher on January 5th, 2010
No Comments »

Stories We Love to Hear

Jim Schutz
Oculus Chief Operating Officer

The team at Oculus loves to share patient stories, in the lunch room, during the long commutes fighting California’s (and Seattle’s – R&D is in Seattle) traffic and today, on our investor dialogue site, As We See It.

A terrific new patient story made the rounds this week, this one from Phoenix, Arizona.

Posted in Patient Success Stories by Jim Schutz on November 30th, 2009
No Comments »

Categories